LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding LENZ Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 63 | 1 | 66 | +4 |
| Shares | 29.6M | 20 | 28.8M | −815.9K (−2.8%) |
| Value | $93.9M | $63 | $95.6M | +$1.72M (+1.8%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held LENZ Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 112,176 | $358.8K | 0.12% |
| Bank of Montreal | 82,400 | $273.6K | 0.00% |
| 683 Capital Management, LLC | 52,306 | $173.7K | 0.02% |
| Susquehanna International Group, LLP | 33,635 | $111.7K | 0.00% |
| Boothbay Fund Management, LLC | 28,463 | $94.5K | 0.00% |
| K2 Principal Fund, L.P. | 28,424 | $94.4K | 0.03% |
| Acadian Asset Management LLC | 25,799 | $85.0K | 0.00% |
| Belvedere Trading LLC | 22,121 | $73.4K | 0.04% |
| Annandale Capital, LLC | 17,930 | $60.0K | 0.02% |
| Lodestar Private Asset Management LLC | 14,199 | $47.1K | 0.01% |
| Lazard Asset Management LLC | 2,206 | $7.00K | 0.00% |
| Royal Bank of Canada | 7 | $0 | 0.00% |
| Steward Financial Group LLC | 13 | $0 | 0.00% |
Sold out (9)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| OrbiMed Advisors LLC | 848,412 | $2.69M |
| Opaleye Management Inc. | 577,250 | $1.83M |
| New York Life Investments Alternatives | 25,333 | $80.0K |
| Schonfeld Strategic Advisors LLC | 23,600 | $75.0K |
| ExodusPoint Capital Management, LP | 12,836 | $41.0K |
| Jane Street Group, LLC | 11,542 | $37.0K |
| Jump Financial, LLC | 10,800 | $34.0K |
| LMR Partners LLP | 10,530 | $33.0K |
| BNP Paribas Arbitrage, SA | 312 | $989 |
Not filed for Q4 2022 yet (1)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Portfolios Advisors | 20 | $63 |